CDH Investments’ Acquire $1.4 Billion Acquisition of Sirtex

Paul Hastings has advised CDH Genetech Limited (“CDH”), part of the CDH Investments group, on its agreement (together with Hong Kong-listed China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”)) to enter into a Scheme Implementation Deed with Australian-based medical device company Sirtex Medical Limited (“Sirtex”) to acquire all the issued shares of Sirtex for A$33.60 per share in cash through a Scheme of Arrangement.

On a fully diluted basis, the CDH-CGP Scheme represents a total equity purchase price for Sirtex of approximately US$1.4 billion. Lazard is acting as sole financial advisor to CDH.

CDH is a dedicated alternative asset fund manager with approximately US$20 billion of assets under management. CDH plans to invest in Sirtex to ensure its continued success and enhance its growth prospects globally in existing and new markets.

The Paul Hastings team was led by Raymond Li (Picture), partner and Chair of Greater China, and corporate partner Vivian Lam, with support from Fang Pei, Jeff Lee, Hulka Lo and May Lun in Hong Kong; Sophie Han in Shanghai; Robert Silvers, Scott Hataway, Scott Flicker, Charles Patrizia, Quinn Dang, and Reade Jacob in Washington, D.C.; David Shine, Vincent Buehler and Jordan Goldman in New York; Tiffany Lee in Palo Alto; Regina Engelstädter and Sebastian Klein in Frankfurt; and Pierre Kirch in Paris.


Involved fees earner: Raymond Li – Paul Hastings; Fang Pei – Paul Hastings; Jeff Lee – Paul Hastings; Hulka Lo – Paul Hastings; May Lun – Paul Hastings; Sophie Han – Paul Hastings; David Shine – Paul Hastings; Vinnie Buehler – Paul Hastings; Jordan Goldman – Paul Hastings; Regina Engelstaedter – Paul Hastings; Sebastian Klein – Paul Hastings; Vivian Lam – Paul Hastings; Robert Silvers – Paul Hastings; Reade Jacob – Paul Hastings; Scott Hataway – Paul Hastings; Scott Flicker – Paul Hastings; Quinn Dang – Paul Hastings; Charles Patrizia – Paul Hastings; Tiffany Lee – Paul Hastings;

Law Firms: Paul Hastings;

Clients: CDH Investments;